Why do metabolites circulate?

References

• Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, Shipley LA. (2002). Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188–196.
   PubMed Web of Science ®Google Scholar
• Brammer KW, Coakley AJ, Jezequel SG, Tarbit MH. (1991). The disposition and metabolism of [14C]fluconazole in humans. Drug Metab Dispos 19:764–767.
   PubMed Web of Science ®Google Scholar
• Chandrasekaran A, McKeand WE, Sullivan P, DeMaio W, Stoltz R, Scatina J. (2009). Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women. Drug Metab Dispos 37:1219–1225.
   PubMed Web of Science ®Google Scholar
• Chou KC. (2010). Graphic rule for drug metabolism systems. Curr Drug Metab 11:369–378.
   PubMed Web of Science ®Google Scholar
• Christopher LJ, Hong H, Vakkalagadda BJ, Clemens PL, Su H, Roongta V, Allentoff A, Sun H, Heller K, Harbison CT, Iyer RA, Humphreys WG, Wong T, Zhang S. (2010). Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans. Drug Metab Dispos 38:2049–2059.
   PubMed Web of Science ®Google Scholar
• Chu XY, Huskey SE, Braun MP, Sarkadi B, Evans DC, Evers R. (2004). Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3. J Pharmacol Exp Ther 309:156–164.
   PubMed Web of Science ®Google Scholar
• Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. (1987). Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humans. Clin Pharmacol Ther 42:535–541.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Cosker T, Boyden T, Zhou S, Schroeder C, Potchoiba MJ. (2008). Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: Assessment of the metabolic profile of CP-544439 in plasma and urine of humans. Drug Metab Dispos 36:1869–1883.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, Bu HZ, Smith DA. (2009). Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357–368.
   PubMed Web of Science ®Google Scholar
• de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA. (2009). Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn 36:541–564.
   PubMed Web of Science ®Google Scholar
• Enokizono J, Kusuhara H, Sugiyama Y. (2007). Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab Dispos 35:209–214.
   PubMed Web of Science ®Google Scholar
• Hayball PJ, Nation RL, Bochner F. (1992). Stereoselective interactions of ketoprofen glucuronides with human plasma protein and serum albumin. Biochem Pharmacol 44:291–299.
   PubMedGoogle Scholar
• Herédi-Szabó K, Glavinas H, Kis E, Méhn D, Báthori G, Veres Z, Kóbori L, von Richter O, Jemnitz K, Krajcsi P. (2009). Multidrug resistance protein 2-mediated estradiol-17β-D-glucuronide transport potentiation: In vitro-in vivo correlation and species specificity. Drug Metab Dispos 37:794–801.
   PubMed Web of Science ®Google Scholar
• Hirohashi T, Suzuki H, Sugiyama Y. (1999). Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem 274:15181–15185.
   PubMed Web of Science ®Google Scholar
• Hirouchi M, Kusuhara H, Onuki R, Ogilvie BW, Parkinson A, Sugiyama Y. (2009). Construction of triple-transfected cells [organic anion-transporting polypeptide (OATP) 1B1/multidrug resistance-associated protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for analysis of the sinusoidal function of MRP3 and MRP4. Drug Metab Dispos 37:2103–2111.
   PubMed Web of Science ®Google Scholar
• Hochner-Celnikier D. (1999). Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol 85:23–29.
   PubMed Web of Science ®Google Scholar
• Jeong EJ, Liu X, Jia X, Chen J, Hu M. (2005). Coupling of conjugating enzymes and efflux transporters: Impact on bioavailability and drug interactions. Curr Drug Metab 6:455–468.
   PubMed Web of Science ®Google Scholar
• John BA, Brodie RR, Baldock GA, McBurney A, Chasseaud LF, Jank P, Von Nieciecki A. (2002). Pharmacokinetics and metabolism of the anti-oestrogen droloxifene in female human subjects. Xenobiotica 32:699–713.
   PubMed Web of Science ®Google Scholar
• Lagas JS, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. (2010). Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Mol Pharmacol 77:687–694.
   PubMed Web of Science ®Google Scholar
• Lau YY, Okochi H, Huang Y, Benet LZ. (2006). Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: Application of in vitro and ex situ systems. J Pharmacol Exp Ther 316:762–771.
   PubMed Web of Science ®Google Scholar
• Lee WK, Reichold M, Edemir B, Ciarimboli G, Warth R, Koepsell H, Thévenod F. (2009). Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule. Am J Physiol Renal Physiol 296:F1504–F1513.
   PubMed Web of Science ®Google Scholar
• Lenz EM, Spear M, Drake C, Pollard CR, Ward M, Schulz-Utermoehl T, Harrison M. (2010). Characterisation and identification of the human N+-glucuronide metabolite of cediranib. J Pharm Biomed Anal 53:526–536.
   PubMedGoogle Scholar
• Ling KH, Leeson GA, Burmaster SD, Hook RH, Reith MK, Cheng LK. (1995). Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab Dispos 23:631–636.
   PubMed Web of Science ®Google Scholar
• Loi CM, Alvey CW, Vassos AB, Randinitis EJ, Sedman AJ, Koup JR. (1999a). Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites. J Clin Pharmacol 39:920–926.
   PubMed Web of Science ®Google Scholar
• Loi CM, Young M, Randinitis E, Vassos A, Koup JR. (1999b). Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 37:91–104.
   PubMed Web of Science ®Google Scholar
• Mashayekhi SO, Ghandforoush-Sattari M, Buss DC, Routledge PA, Hain RDW. (2010). Impact of anti-cancer drugs and other determinants on serum protein binding of morphine 6-glucuronide. DARU 18:107–113.
   PubMedGoogle Scholar
• Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, Kusuhara H, Sugiyama Y. (2008). Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol 73:1474–1483.
   PubMed Web of Science ®Google Scholar
• Merino G, Jonker JW, Wagenaar E, Pulido MM, Molina AJ, Alvarez AI, Schinkel AH. (2005). Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab Dispos 33:614–618.
   PubMed Web of Science ®Google Scholar
• Milne RW, Nation RL, Somogyi AA. (1996). The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Rev 28:345–472.
   PubMed Web of Science ®Google Scholar
• Morgan DJ, Paull JD, Richmond BH, Wilson-Evered E, Ziccone SP. (1986). Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol 22:587–593.
   PubMed Web of Science ®Google Scholar
• Neugebauer G, Akpan W, von Möllendorff E, Neubert P, Reiff K. (1987). Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol 10 Suppl 11:S85–S88.
   PubMedGoogle Scholar
• Price DA, Blagg J, Jones L, Greene N, Wager T. (2009). Physicochemical drug properties associated with in vivo toxicological outcomes: A review. Expert Opin Drug Metab Toxicol 5:921–931.
   PubMed Web of Science ®Google Scholar
• Sallustio BC, Fairchild BA, Pannall PR. (1997). Interaction of human serum albumin with the electrophilic metabolite 1-O-gemfibrozil-β-D-glucuronide. Drug Metab Dispos 25:55–60.
   PubMed Web of Science ®Google Scholar
• Schultz B, Aaes-Jørgensen T, Bøgesø KP, Jørgensen A. (1981). Preliminary studies on the absorption, distribution, metabolism, and excretion of THIP in animal and man using 14C-labelled compound. Acta Pharmacol Toxicol (Copenh) 49:116–124.
   PubMedGoogle Scholar
• Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, Sugiyama Y. (2005). Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33:1477–1481.
   PubMed Web of Science ®Google Scholar
• Sisenwine SF, Liu AL, Tio C, Kimmel H, Freeland G. (1986). The metabolic disposition of 14C-ciramadol in humans. Xenobiotica 16:335–340.
   PubMed Web of Science ®Google Scholar
• Smith DA. (2011). Discovery and ADMET: Where are we now. Curr Top Med Chem 11:467–481.
   PubMed Web of Science ®Google Scholar
• Smith DA, Obach RS. (2010). Metabolites: Have we MIST out the importance of structure and physicochemistry? Bioanalysis 2:1223–1233.
   PubMed Web of Science ®Google Scholar
• Smith DA, Obach RS, Williams DP, Park BK. (2009). Clearing the MIST (metabolites in safety testing) of time: The impact of duration of administration on drug metabolite toxicity. Chem Biol Interact 179:60–67.
   PubMed Web of Science ®Google Scholar
• Smith DA, Obach RS. (2009). Metabolites in safety testing (MIST): Considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 22:267–279.
   PubMed Web of Science ®Google Scholar
• Smith DA, Obach RS. (2005). Seeing through the mist: Abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab Dispos 33:1409–1417.
   PubMed Web of Science ®Google Scholar
• Smith DA, Obach RS. (2006). Metabolites and safety: What are the concerns, and how should we address them? Chem Res Toxicol 19:1570–1579.
   PubMed Web of Science ®Google Scholar
• Tahara H, Kusuhara H, Maeda K, Koepsell H, Fuse E, Sugiyama Y. (2006). Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos 34:743–747.
   PubMed Web of Science ®Google Scholar
• Tian X, Swift B, Zamek-Gliszczynski MJ, Belinsky MG, Kruh GD, Brouwer KL. (2008). Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab Dispos 36:911–915.
   PubMed Web of Science ®Google Scholar
• van de Wetering-Krebbers SF, Jacobs PL, Kemperman GJ, Spaans E, Peeters PA, Delbressine LP, van Iersel ML. (2011). Metabolism and excretion of asenapine in healthy male subjects. Drug Metab Dispos 39:580–590.
   PubMed Web of Science ®Google Scholar
• Veerbeck R, Tjandramaga TB, Verberckmoes R, De Schepper PJ. (1976). Biotransformation and excretion of lorazepam in patients with chronic renal failure. Brit J Clin Pharmacol 3:1033–1039.
   PubMedGoogle Scholar
• Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, Chen L, Dilzer S, Lasseter K, Gottesdiener K, Wagner JA, Herman GA. (2007). Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 35:533–538.
   PubMed Web of Science ®Google Scholar
• Vos RM, Krebbers SF, Verhoeven CH, Delbressine LP. (2002). The in vivo human metabolism of tibolone. Drug Metab Dispos 30:106–112.
   PubMed Web of Science ®Google Scholar
• Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP. (1995). Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. Br J Clin Pharmacol 39:692–695.
   PubMed Web of Science ®Google Scholar
• Wang L, Munsick C, Chen S, Bonacorsi S, Cheng PT, Humphreys WG, Zhang D. (2011). Metabolism and disposition of 14C-labeled peliglitazar in humans. Drug Metab Dispos 39:228–238.
   PubMedGoogle Scholar
• Yabuki M, Iba K, Nakatsuka I, Yoshitake A. (1994a). Entero-hepatic recirculation of SM-10888 in the rat: Elucidation of the participating major metabolites. Yakubutsu Dotai 9:596–602.
   Google Scholar
• Yabuki M, Mine T, Iba K, Nakatsuka I, Yoshitake A. (1994b). Pharmacokinetics of SM-10888 and its metabolites depending on their physicochemical properties. Drug Metab Dispos 22:294–297.
   PubMedGoogle Scholar
• Yu L, Qian M, Liu Y, Yao T, Zeng S. (2010). Stereoselective metabolism of propranolol glucuronidation by human UDP-glucuronosyltransferases 2B7 and 1A9. Chirality 22:456–461.
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa K, Brouwer KL. (2006a). Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J Pharmacol Exp Ther 319:459–467.
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, Brouwer KL. (2006b). Integration of hepatic drug transporters and phase II metabolizing enzymes: Mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci 27:447–486.
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Nezasa K, Tian X, Bridges AS, Lee K, Belinsky MG, Kruh GD, Brouwer KL. (2006c). Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-/- and Abcc4-/- mice. J Pharmacol Exp Ther 319:1485–1491.
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, Brouwer KL. (2006d). The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol Pharmacol 70:2127–2133.
   PubMed Web of Science ®Google Scholar
• Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P. (2001). Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 276:46400–46407.
   PubMed Web of Science ®Google Scholar
• Zelcer N, van de Wetering K, Hillebrand M, Sarton E, Kuil A, Wielinga PR, Tephly T, Dahan A, Beijnen JH, Borst P. (2005). Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci USA 102:7274–7279.
   PubMed Web of Science ®Google Scholar
• Zhang D, Raghavan N, Wang L, Xue Y, Obermeier M, Chen S, Tao S, Zhang H, Cheng PT, Li W, Ramanathan R, Yang Z, Humphreys WG. (2011). Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: How circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment. Drug Metab Dispos 39:123–131.
   PubMed Web of Science ®Google Scholar
• Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, Li Y. (2008). Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 15:1981–2039.
   PubMed Web of Science ®Google Scholar